Health Care & Life Sciences » Pharmaceuticals | Hwail Pharmaceutical Co. Ltd.

Hwail Pharmaceutical Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Sales/Revenue
94,166
96,103
106,130
111,519
102,463
Cost of Goods Sold (COGS) incl. D&A
78,450
82,303
96,706
97,064
87,570
Gross Income
15,716
13,800
9,424
14,454
14,893
SG&A Expense
10,020
8,976
7,261
12,051
10,750
EBIT
5,566
4,638
1,952
2,278
3,906
Unusual Expense
-
19
-
100
937
Non Operating Income/Expense
43
33
5,900
8,169
2,120
Interest Expense
721
574
745
706
505
Pretax Income
5,300
4,408
7,279
9,825
3,448
Income Tax
1,090
276
1,826
1,824
782
Equity in Affiliates
-
-
-
1,620
-
Consolidated Net Income
4,209
4,132
5,453
6,382
2,665
Net Income
4,209
4,132
5,453
6,382
2,665
Net Income After Extraordinaries
4,209
4,132
5,453
6,382
2,665
Net Income Available to Common
4,209
4,132
5,453
6,382
2,665
EPS (Basic)
312.00
306.00
403.00
472.00
197.00
Basic Shares Outstanding
13
14
14
14
14
EPS (Diluted)
311.28
305.54
403.25
471.91
197.10
Diluted Shares Outstanding
14
14
14
14
14
EBITDA
6,989
6,509
4,723
5,191
6,633
Other Operating Expense
130
186
211
125
237
Non-Operating Interest Income
411
396
173
184
215
Equity in Affiliates (Pretax)
-
-
-
-
1,351

About Hwail Pharmaceutical Co.

View Profile
Address
57 Jeyakgongdan 3-gil
Hwaseong GY 18622
Korea, Republic Of
Employees -
Website http://www.hwail.com
Updated 09/14/2018
HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following businesses: Pharmaceutical Raw Material, Cephalosporin Antibiotic, Functional Health Food Ingredient. Its products include antitussive expectorants, spasmolytic, stomach function modifier, anti-inflammatory and others.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.